{"public_id":"cl_9425c0e5ac7503be49ee1374bb2b5c7f","status":"active","superseded_by_public_id":null,"corpus_id":382332,"text":"Phase 1 treatment with 960 mg twice daily produced an 81% response rate in metastatic melanoma patients.","confidence":0.98,"paper":{"corpus_id":382332,"title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","url":"https://sah.borca.ai/papers/382332"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_5f4fba9beccd635693ef3a561de7c0a8","name":"Phase 1 clinical trials","description":"Early-stage human trials used to evaluate safety and preliminary efficacy.","types":["clinical trial phase"],"url":"https://sah.borca.ai/concepts/co_5f4fba9beccd635693ef3a561de7c0a8"},{"public_id":"co_7c29e833dac77dae4574172b850b49db","name":"metastatic melanoma patients","description":"Patients with melanoma that had spread beyond the original site.","types":["patient population"],"url":"https://sah.borca.ai/concepts/co_7c29e833dac77dae4574172b850b49db"},{"public_id":"co_b8f227a68ed135317063f2db4d108128","name":"960 mg twice daily","description":"The oral dosing regimen used for the reported metastatic melanoma cohort.","types":["dose"],"url":"https://sah.borca.ai/concepts/co_b8f227a68ed135317063f2db4d108128"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_9425c0e5ac7503be49ee1374bb2b5c7f"}